Phase II trial (Investigator-initiated clinical trial) of CH5424802 in patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma

Trial Profile

Phase II trial (Investigator-initiated clinical trial) of CH5424802 in patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Alectinib (Primary)
  • Indications Anaplastic large cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 22 Apr 2016 Planned End Date changed from 31 Dec 2017 to 21 Feb 2016.
    • 22 Apr 2016 Planned End Date changed from 21 Feb 2016 to 31 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top